CSL Of Australia Cleared To Market H1N1 Flu Vaccine By End Of Month
This article was originally published in PharmAsia News
Australia's CSL has been cleared to market its H1N1 flu vaccine in the country, with the first doses to be available by the end of September
You may also be interested in...
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.